Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 35, 2008, Pages 12780-12784

  Stevens, Richard C ^a   Suzuki, Stephanie M ^a   Cole, Toby B ^a   Park, Sarah S ^a   Richter, Rebecca J ^a   Furlong, Clement E ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Engineered PON1; Escherichia coli produced human PON1; Therapeutic PON1

Indexed keywords

ORGANOPHOSPHATE; RECOMBINANT ENZYME; RECOMBINANT HUMAN PARAOXONASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PURIFICATION; ESCHERICHIA COLI; INTOXICATION; KNOCKOUT MOUSE; LETHAL DOSE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

ANIMALS; ARYLDIALKYLPHOSPHATASE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ESCHERICHIA COLI; HUMANS; HYDROLYSIS; INJECTIONS, INTRAPERITONEAL; KINETICS; MICE; PHOSPHORIC ACID ESTERS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; STAPHYLOCOCCAL PROTEIN A;

ESCHERICHIA COLI; MUS;

EID: 51349097915     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0805865105     Document Type: Article

References (31)

1. World Health Organization (1986) Informal Consultation on Planning Strategy for the Prevention of Pesticide Poisoning (WHO, Geneva), WHO/VBC/86.926.
2. World Health Organization (1990) Public Health Impact of Pesticides Used in Agriculture (WHO, Geneva).
3. Aldridge WN, Davison AN (1953) The mechanism of inhibition of cholinesterases by organophosphorus compounds. Biochem J 55:763-766.
4. Johnson MK (1982) The target for initiation of delayed neurotoxicity by organophosphorus esters: Biochemical studies and toxicological applications. Rev Biochem Toxicol 4:141-212.
5. Shih TM, McDonough JH (1999) Organophosphorus nerve agent-induced seizures and efficacy of atropine sulfate as anticonvulsant treatment: Pharmacologic mechanisms. Pharmacol Biochem Behav 64:147-153.
6. Rusyniak DE, Nañagas KA (2004) Organophosphate poisoning. Semin Neurol 24:197-204.
7. Broomfield CA, et al. (1999) Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates. J Pharmacol Exp Ther 259:633-638.
8. Saxena A, et al. (2006) Bioscavenger for protection from toxicity of organophosphorus compounds. J Mol Neurosci 30:145-148.
9. Lenz DE, et al. (2007) Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: A mini review. Toxicology 233:31-39.
10. Aldridge WN (1953) Serum esterases, II: An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera. Biochem J 53:117-124.
11. Geldmacher-von Mallinckrodt M, Diepgen TL (1988) The human serum paraoxonase: Polymorphism and specificity. Toxicol Environ Chem 18:79-196.
12. Davies H, et al. (1996) The human serum paraoxonase polymorphism is reversed with diazoxon, soman, and sarin. Nat Genet 14:334-336.
13. Costa LG, et al. (1990) Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol Appl Pharmacol 103:66-76.
14. Li W-F, Costa LG, Furlong CE (1993) Serum paraoxonase status: A major factor in determining resistance to organophosphates. J Toxicol Environ Health 40:337-346.
15. Li W-F, et al. (2000) Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10:767-779.
16. Li W-F, Furlong C, Costa LG (1995) Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett 76:219-226.
17. Bernard P, Couturier M (1992) Cell killing by the F plasmid CcdB protein involves poisoning of DNA-topoisomerase II complexes. J Mol Biol 226:735-745.
18. Jarvik GP, et al. (2000) Paraoxonase phenotype is a better predictor of vascular disease than PON1192 or PON155 genotype. Atheroscler Thromb Vasc Biol 20:2442-2447.
19. Harel M, et al. (2007) The 3-D structure of serum paraoxonase 1 sheds light on its activity, stability, solubility, and crystallizability. Arh Hig Rada Toksikol 58:347-353.
20. Sinan S, Kockar F, Arslan O (2006) Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin- and aminoglycoside-derived antibiotics. Biochimie 88:565-574.
21. Golmanesh L, Mehrani H, Tabei M (2007) Simple procedures for purification and stabilization of human serum paraoxonase-1. J Biochem Biophys Methods 70:1037-1042.
22. Gan KN, Smolen A, Eckerson HW, La Du BN (1991) Purification of human serum paraoxonase/arylesterase: Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19:100-106.
23. Hassett C, et al. (1991) Characterization of cDNA clones encoding rabbit and human serum paraoxonase: The mature protein retains its signal sequence. Biochemistry 30:10141-10149.
24. Taylor JW, Ott J, Eckstein F (1985) The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate- modified DNA. Nucleic Acids Res 13:8765-8785.
25. Willis RC, et al. (1974) Preparation of the periplasmic binding proteins from Salmonella typhimurium and Escherichia coli. Arch Biochem Biophys 161:64-75.
26. Furlong CE, Richter RJ, Seidel SL, Costa LG, Motulsky AG (1989) Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal Biochem 180:242-247.
27. Richter RJ, Furlong CE (1999) Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9:745-753.
28. Furlong CE, Richter RJ, Seidel SL, Motulsky AG (1988) Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos-oxon and paraoxon. Am J Hum Genet 43:230-238.
29. Dowd JE, Riggs DS (1965) A comparison of estimates of Michaelis-Menten kinetics constants from various linear transformations. J Biol Chem 240:863-869.
30. Shih DM, et al. (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284-287.
31. Cole TB, et al. (2005) Toxicity of chlorpyrifos and chlorpyrifos-oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet Genomics 15:589-598.